Command Palette

Search for a command to run...

Clinical Trials · NCT03936933

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

TerminatedPhase 3Gonadorelin (Prohibited)
Phase
Phase 3
Recruitment status
Terminated
Sponsor
Eurofarma Laboratorios S.A.
Enrollment
6
Start date
Oct 2020
Locations
1 site, India
Primary endpoint
To evaluate and compare the pharmacodynamics
View Gonadorelin compound reference